ArticleAlpha psychiatry2025
Effect of Paliperidone Combined with Sertraline in the Treatment of Schizophrenia and its Influence on Serum Neurofunctional Related Factors.
Article in Alpha psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Efficacy of sertraline combined with low-dose antipsychotics in first-episode schizophrenia.European archives of psychiatry and clinical neuroscience · 2026Article
- Cognitive behavioral therapy combined with aripiprazole in the treatment of schizophrenia: effects on cognitive function and psychological state.Frontiers in psychiatry · 2026Article
- Linking Metabolic Disorders and Immune System Phenomena in Schizophrenia: The Role of Adipose Tissue and Inflammation.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the efficacy of paliperidone combined with sertraline in treating schizophrenia (SCZ) and its effect on serum neurofunctional factors. Methods: A retrospective analysis was conducted on SCZ patients admitted between June 2020 and June 2021. Initially, 80 patients were treated with paliperidone, while 36 received a combination of paliperidone and sertraline. Propensity score matching based on 3 covariates resulted in 2 groups: the control group (paliperidone alone, n = 36) and the observation group (paliperidone + sertraline, n = 36). The clinical efficacy, adverse reactions, quality of life scores, serum biomarkers levels related to nerve and liver function, and anxiety and depression levels were compared between the 2 groups. Results: The observation group demonstrated higher total effectiveness than the control group ( Conclusions: Paliperidone combined with sertraline effectively improves serum neuregulin levels in SCZ patients, alleviates negative emotional effects without causing liver or kidney damage, and demonstrates excellent clinical efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.